ArticleGynecologic oncology reports2022
Iris metastasis from endometrial carcinoma: A challenging diagnosis and individualized eye-sparing treatment.
Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Impact of Chemotherapy and Radiotherapy on Iris Metastases: A Case Report.Ocular oncology and pathology · 2026Article
- [Clinical approach for solid intraocular metastases].Die Ophthalmologie · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A woman in her 70's with a history of recurrent oral aphthosis and two years earlier of resected stage IA low risk endometrial adenocarcinoma, presented with blurred vision and a painful mass of the right eye that had developed in two months. PET/CT imaging detected a nodule in the right lung. Because of diagnostic uncertainties between inflammatory disease (Behçet syndrome) or cancer, a biopsy of iris and pulmonary lesions were performed and lead to histologically documented metastases from endometrial adenocarcinoma in both sites. After a multidisciplinary team discussion excluding disfiguring local therapies (radiation therapy or surgery), systemic chemotherapy with carboplatin and paclitaxel was performed, leading to radiological complete response that is sustained at 12 months after the end of treatment. This case shows that chemotherapy should be considered as a valid organ-sparing treatment in the management of these uncommon metastatic sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.